ArticleInternational journal of clinical oncology2026
Guideline-concordant treatment and clinical outcomes in older patients with endometrial cancer in Japan: a retrospective single-institution study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate achievement of Japanese guideline-concordant treatment (J-GCT) and examine its association with clinical outcomes among older patients with endometrial cancer.
methodsWe retrospectively reviewed 130 patients aged ≥ 70 years diagnosed between 2010 and 2019. J-GCT was defined as receipt of primary surgery, standard surgical staging including lymph node assessment when indicated, and risk-adapted adjuvant chemotherapy. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier methods and log-rank tests. Multivariable Cox models evaluated factors associated with PFS.
resultsJ-GCT achievement was significantly lower in patients aged ≥ 75 years than in those aged 70-74 years (28.1% vs. 71.2%, P < 0.001). Patients aged ≥ 75 years less frequently underwent primary surgery (84.2% vs 97.3%, P = 0.011) and lymph node assessment (45.8% vs 80.3%, P < 0.001). Adjuvant chemotherapy for intermediate- or high-risk disease was less frequently administered in patients aged ≥ 75 years (38.7% vs 86.4%, P < 0.001). Perioperative complications were infrequent, and no treatment-related deaths were observed. J-GCT achievement was associated with improved PFS (P < 0.001) and OS (P = 0.004). In multivariable analysis adjusting for age and selected clinicopathologic factors, failure to achieve J-GCT remained associated with inferior PFS (adjusted hazard ratio 3.20, 95% confidence interval 1.43-7.15; P = 0.005).
conclusionJ-GCT achievement was lower among patients aged ≥ 75 years, particularly with respect to lymph node assessment and risk-adapted adjuvant chemotherapy. Failure to achieve J-GCT was associated with inferior PFS after adjustment, although this group included heterogeneous treatment patterns with potentially different prognostic implications. These findings support treatment decision-making based on structured clinical evaluation rather than chronological age alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.